CoolIT Systems Drives Further Adoption of Direct Liquid Cooling to Enable Demanding HPC and AI
Coolers

CoolIT Systems Drives Further Adoption of Direct Liquid Cooling to Enable Demanding HPC and AI

CoolIT Systems collaborates with industry leaders to support advanced research and new scientific discoveries through high performance computing DALLAS (PRWEB) NOVEMBER 12, 2018 - CoolIT Systems, the world leader in modular, scalable data center liquid cooling technology, is announcing details of new customer collaborations and high-density Direct Liquid Cooling products at Supercomputing 2018...

Read More »
Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and Obese
Medical Equipment

Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and Obese

BRIDGEWATER, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,wearable insulin delivery option for patients with diabetes, announced today a poster titled “Relationship between Baseline BMI and Clinical Outcomes with V-Go® Wearable Insulin Delivery Device in...

Read More »
Valeritas’ V-Go-® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and Obese
Medical Equipment

Valeritas’ V-Go-® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and Obese

BRIDGEWATER, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,wearable insulin delivery option for patients with diabetes, announced today a poster titled “Relationship between Baseline BMI and Clinical Outcomes with V-Go® Wearable Insulin Delivery Device in...

Read More »
PI Introduces A-341 XY/XYZ Positioning Stage That Provides Dynamic Error Mapping
Positioners

PI Introduces A-341 XY/XYZ Positioning Stage That Provides Dynamic Error Mapping

The A-341 Hybrid Gantry XY/XYZ Positioning Stage is offered with a frictionless air bearing guiding system and a unique hybrid bearing design. The stage offers 300 x 300 to 500 x 1000 mm XY travel and 2 m/sec maximum velocity. The product is equipped with absolute measuring encoders and ironless linear motors that eliminate cogging. The device is suitable for step and scan applications. It comes...

Read More »
PI Introduces A-341 XY/XYZ Positioning Stage That Provides Dynamic Error Mapping
Positioners

PI Introduces A-341 XY/XYZ Positioning Stage That Provides Dynamic Error Mapping

The A-341 Hybrid Gantry XY/XYZ Positioning Stage is offered with a frictionless air bearing guiding system and a unique hybrid bearing design. The stage offers 300 x 300 to 500 x 1000 mm XY travel and 2 m/sec maximum velocity. The product is equipped with absolute measuring encoders and ironless linear motors that eliminate cogging. The device is suitable for step and scan applications. It comes...

Read More »
Medical Balloons

12-Month Data from Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018

Study met primary endpoint and all 12-month secondary safety endpoints including 100 percent freedom from CD-TLR or TVR Results demonstrated continued clinically significant improvement in ABI, walking distance, walking speed and stair-climbing scores at 12 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic...

Read More »
Medical Balloons

12-Month Data from Surmodics SurVeil-® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018

Study met primary endpoint and all 12-month secondary safety endpoints including 100 percent freedom from CD-TLR or TVR Results demonstrated continued clinically significant improvement in ABI, walking distance, walking speed and stair-climbing scores at 12 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic...

Read More »
Aktina Showcased Latest Advancements for Cancer Treatment Accuracy and Patient Immobilization at ASTRO 2018
Medical Equipment

Aktina Showcased Latest Advancements for Cancer Treatment Accuracy and Patient Immobilization at ASTRO 2018

Congers, NY (November 6, 2018) Aktina Medical, the industry's primary source for radiation oncology needs, leveraged its participation at the ASTRO show's 60th Annual Meeting by showcasing the company's latest advancements for improved radiosurgery accuracy, and patient immobilization and comfort. Featured Aktina solutions on display at ASTRO 2018 included its SenoView prone breast system,...

Read More »

All Topics